Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology
BBM testing, compared with PET scan alone, is more efficient in the utilization of available amyloid PET scans and is cost-effective for assessment of Alzheimer's disease pathology in patients with signs and symptoms of cognitive decline.
Authors
- Robert Lagier (ORCID: https://orcid.org/0000-0002-0053-7305)
- Michael K. Racke (ORCID: https://orcid.org/0000-0002-1231-4694)
- Yuri A. Fesko
Institutions
- Quest Diagnostics (United States) (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1016/j.tjpad.2025.100474
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00